Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide

Jessica Gresham1, Lea S Eiland2,3, Allison M Chung2,41Auburn University, Harrison School of Pharmacy (AUHSOP), 2Department of Pharmacy Practice, AUHSOP, 3University of Alabama, School of Medicine, Huntsville Regional Medical Campus, 4University of South Alabama School of Medicine, Department of Pedi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jessica Gresham, Lea S Eiland, Allison M Chung
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://doaj.org/article/05aa3bf17ca446ef83e9a117b4395041
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:05aa3bf17ca446ef83e9a117b4395041
record_format dspace
spelling oai:doaj.org-article:05aa3bf17ca446ef83e9a117b43950412021-12-02T06:45:05ZTreating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide1176-63281178-2021https://doaj.org/article/05aa3bf17ca446ef83e9a117b43950412010-09-01T00:00:00Zhttp://www.dovepress.com/treating-lennoxndashgastaut-syndrome-in-epileptic-pediatric-patients-w-a5352https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Jessica Gresham1, Lea S Eiland2,3, Allison M Chung2,41Auburn University, Harrison School of Pharmacy (AUHSOP), 2Department of Pharmacy Practice, AUHSOP, 3University of Alabama, School of Medicine, Huntsville Regional Medical Campus, 4University of South Alabama School of Medicine, Department of Pediatrics, Mobile, Alabama, USAAbstract: Lennox–Gastaut syndrome (LGS) is a rare but debilitating pediatric epileptic encephalopathy characterized by multiple intractable seizure types. Treatment of LGS is challenging because of the small number of antiepileptic drugs (AEDs) which are effective for this syndrome, as well as the need for polytherapy in the majority of patients. This review focuses on the treatment of LGS with rufinamide, a recently approved third-generation AED with reported efficacy as adjunctive therapy for LGS. All relevant papers identified through a PubMed search on the treatment of LGS with rufinamide were reviewed. To date, the literature suggests improvements in seizure frequency for pediatric patients with LGS on rufinamide. Rufinamide appears to be especially effective for atonic or drop attack seizures. Rufinamide also displays a favorable adverse event profile compared with the older anticonvulsants, as well as a minimal number of drug interactions, making it a promising option for the adjunctive treatment of seizures associated with LGS.Keywords: epilepsy, Lennox-Gastaut syndrome, pediatrics, seizure, rufinamide Jessica GreshamLea S EilandAllison M ChungDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 639-645 (2010)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Jessica Gresham
Lea S Eiland
Allison M Chung
Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
description Jessica Gresham1, Lea S Eiland2,3, Allison M Chung2,41Auburn University, Harrison School of Pharmacy (AUHSOP), 2Department of Pharmacy Practice, AUHSOP, 3University of Alabama, School of Medicine, Huntsville Regional Medical Campus, 4University of South Alabama School of Medicine, Department of Pediatrics, Mobile, Alabama, USAAbstract: Lennox–Gastaut syndrome (LGS) is a rare but debilitating pediatric epileptic encephalopathy characterized by multiple intractable seizure types. Treatment of LGS is challenging because of the small number of antiepileptic drugs (AEDs) which are effective for this syndrome, as well as the need for polytherapy in the majority of patients. This review focuses on the treatment of LGS with rufinamide, a recently approved third-generation AED with reported efficacy as adjunctive therapy for LGS. All relevant papers identified through a PubMed search on the treatment of LGS with rufinamide were reviewed. To date, the literature suggests improvements in seizure frequency for pediatric patients with LGS on rufinamide. Rufinamide appears to be especially effective for atonic or drop attack seizures. Rufinamide also displays a favorable adverse event profile compared with the older anticonvulsants, as well as a minimal number of drug interactions, making it a promising option for the adjunctive treatment of seizures associated with LGS.Keywords: epilepsy, Lennox-Gastaut syndrome, pediatrics, seizure, rufinamide
format article
author Jessica Gresham
Lea S Eiland
Allison M Chung
author_facet Jessica Gresham
Lea S Eiland
Allison M Chung
author_sort Jessica Gresham
title Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
title_short Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
title_full Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
title_fullStr Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
title_full_unstemmed Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
title_sort treating lennox–gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/05aa3bf17ca446ef83e9a117b4395041
work_keys_str_mv AT jessicagresham treatinglennoxampndashgastautsyndromeinepilepticpediatricpatientswiththirdgenerationrufinamide
AT leaseiland treatinglennoxampndashgastautsyndromeinepilepticpediatricpatientswiththirdgenerationrufinamide
AT allisonmchung treatinglennoxampndashgastautsyndromeinepilepticpediatricpatientswiththirdgenerationrufinamide
_version_ 1718399733892907008